News Release

HYDERABAD, INDIA (06 August 2026) - SUVEN Life Sciences Limited ("Suven") today announced unaudited financial results for the quarter ended 30 June 2026. The unaudited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 06 August 2026 at Hyderabad.

CONSOLIDATED STATEMENT OF OPERATIONS

INR Million, except EPS

	Quarter ended			Year ended
	30-Jun-26	**31-Mar-26**	**30-Jun-25**	**31-Mar-26**
Revenue	*110.89*	*82.98*	*24.67*	*210.45*
R&D and Operational expenses	1,360.69	521.52	526.15	2,916.17
Depreciation and Amortisation	21.55	15.83	13.68	56.14
Finance cost	4.76	1.58	-	1.58
Total expenses	*1,387.00*	*538.93*	*539.83*	*2,973.89*
Exceptional items (insurance claim received)	-	-	-	-
Tax	-	-	-	-
Profit/(Loss) After Tax for the period/year	*(1,276.10)*	*(455.96)*	*(515.17)*	*(2,763.44)*
Other comprehensive income	(0.36)	(4.67)	(0.51)	(11.84)
Total comprehensive income	*(1,276.46)*	*(460.62)*	*(515.68)*	*(2,775.28)*
Paid up equity capital	263.99	263.72	218.07	263.72
Earnings per share of Rs.1 each (EPS)	*(4.84)*	*(2.02)*	*(2.36)*	*(12.13)*

(a) Suven, a Biopharmaceutical company, engaged in Drug Discovery and Development of New Chemical Entities (NCEs) in Central Nervous System (CNS) disorders targeting unmet medical needs, globally.

(b) The statement of operations includes financial of Suven Neurosciences, Inc., a Delaware Company, wholly owned subsidiary (WOS) of Suven, involved in clinical development programs of the Company.

(c) Clinical development pipeline:

- SUVN-502 (Masupirdine) – Achieves 95% Enrollment milestone in Global Phase 3 Trial for Agitation in Alzheimer's Dementia. The completion of patient enrolment by end of September 2026 and last patient last visit will be in quarter 1, 2027 calendar year enabling progression towards database lock and reporting of results potentially in Q2, 2027 calendar year.
- SUVN-G3031 (Samelisant) – Global Phase 3 clinical trial initiated for treatment of EDS in Narcolepsy in April 2026.
- SUVN-911 (Ropanicant) – Successfully completed Phase 2 b clinical trial evaluating the efficacy and safety of Ropanicant in Major Depressive Disorder (MDD).
- SUVN-D4010 (Usmarapride) – Phase 2 PoC (proof of concept) study design being finalized for a cognitive impairment in psychiatric disorder.
- SUVN-I6107 – Phase 1 study for establishing safety and pharmacokinetics completed and preparing for Phase 2 clinical study.

For more information on Suven please visit our Web site at http://www.suven.com

Risk Statement:

Except for historical information, all the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking that involve number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including research and clinical development outcome, outsourcing trends, economic conditions, dependence on collaborative programs, retention of key personnel, technological advances and continued success in growth of revenue that may make our products/services offerings less competitive.